Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20840622 | 1.00 | MAPK1 (0.35) | MAPK1PDE4DPIK3CAKMT2AADORA3 | |
| SCHEMBL20851935 | 1.00 | MAPK1 (0.35) | MAPK1PDE4DPIK3CAKMT2AADORA3 | |
| SCHEMBL15976749 | 0.90 | KMT2A (0.33) | KMT2AADORA3 | |
| SCHEMBL22734104 | 0.88 | KMT2A (0.40) | KMT2AADORA3 | |
| SCHEMBL22734115 | 0.88 | KMT2A (0.38) | KMT2AADORA3 | |
| SCHEMBL22734110 | 0.86 | — | — | |
| SCHEMBL22734105 | 0.86 | KMT2A (0.43) | PDE4DKMT2AADORA3 | |
| SCHEMBL8061460 | 0.84 | KCNH2 (0.36) | MAPK1PDE4DPIK3CA | |
| SCHEMBL10283145 | 0.84 | PIK3CA (0.36) | MAPK1PDE4DPIK3CA | |
| SCHEMBL31474619 | 0.84 | ADORA3 (0.32) | KMT2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3684775-B1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2024-11-20 | — | — | EP | disclosed |
| US-11866445-B2 | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2024-01-09 | — | — | US | disclosed |
| EP-3724195-B1 | SUBSTITUTED TETRAHYDROPYRAN DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2023-12-27 | — | — | EP | disclosed |
| EP-3724194-B1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2023-12-27 | — | — | EP | disclosed |
| CN-117247395-A | PDE4B inhibitors | 武汉人福创新药物研发中心有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-20220281889-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2022-09-08 | — | — | US | disclosed |
| US-11365204-B2 | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2022-06-21 | — | — | US | disclosed |
| US-11365204-B2 | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2022-06-21 | — | — | US | disclosed |
| US-11299497-B2 | Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2022-04-12 | — | — | US | disclosed |
| US-11292799-B2 | Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2022-04-05 | — | — | US | disclosed |
| US-20100305102-A1 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| WO-2010097332-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010097334-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
| WO-2009053268-A1 | NOVEL PHENYL-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009050242-A2 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| EP-2010185-A1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2009-01-07 | — | — | EP | disclosed |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-24 | — | — | US | disclosed |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-24 | — | — | US | disclosed |
| WO-2007118793-A1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007118793-A1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11292799-B2 | Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | PDE2A, PDE5A, PDE3A | MAPK1 2679/4885PDE4D 12/4885PIK3CA 475/4885 |
| US-20220281889-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE7A, PDE12 | MAPK1 2254/4885PDE4D 11/4885PIK3CA 978/4885 |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | PDE4A, PDE4B, PDE12 | MAPK1 1693/4885PDE4D 12/4885PIK3CA 278/4885 |
| US-11299497-B2 | Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | PDE5A, PDE4A, PDE7A | MAPK1 2576/4885PDE4D 11/4885PIK3CA 416/4885 |
| US-20100305102-A1 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | SULT2A1, DPYD, HRH2 | MAPK1 2046/4885PDE4D 3773/4885PIK3CA 554/4885 |
| US-11365204-B2 | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | PDE4A, PDE7A, PDE12 | MAPK1 2254/4885PDE4D 11/4885PIK3CA 978/4885 |
| US-11866445-B2 | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | PDE4A, PDE7A, PDE12 | MAPK1 2254/4885PDE4D 11/4885PIK3CA 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.